- Danish stocks
- Norwegian stocks
- Swedish stocks
- AktieTorget
- A1M Pharma
- Accelerator Nordic
- AlphaHelix
- AroCell
- Biotech-IgG
- Brighter
- Clinical Laserthermia
- Emotra
- Enzymtica
- Eurocine Vaccines
- European Inst. of Science
- IDL Biotech
- Medfield Diagnostics
- MedicPen
- MediRox
- MediRätt
- Micropos Medical
- PharmaLundensis
- Respiratorius
- Rubicon Life Science
- SensoDetect
- WntResearch
- Orasolv
- Senzime
- SPAGO Imaging
- Vivoline Medical
- First North Stockholm
- OMX Stockholm A-F
- OMX Stockholm G-Z
- AktieTorget
- US stocks
- General discussion
- All posts
[…] An amazing survey – it’s a MUST read 🙂 NEW PATENT: Methods For Rapid Assessment of Severity of a Trauma […]
That is – what we call – a good question 🙂 Surely there must be more than a slight frown in Alere's and Abbotts headquarters – in december their patent for measurement is revoked – and in january a complimentary patent is issued to BioPorto.
If I understand the issued patent correctly – then it not only covers injuries from war / natural disasters (as I believe was the original intention) but now all injuries originating from physical trauma (within 6 hours) – assuming this is correct then all use in emergency rooms should be covered per se.
When CCH (Alere/Abbott) to BioPorto to court – they had their own patent to build a case on – this is not the case anymore (at least not unless they appeal the annullment)